Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) issued its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07, FiscalAI reports. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The business had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.15 million.

Coya Therapeutics Price Performance

Shares of COYA stock traded up $0.04 on Tuesday, hitting $4.22. The stock had a trading volume of 391,325 shares, compared to its average volume of 184,805. The business has a 50 day moving average of $4.39 and a 200 day moving average of $5.09. The stock has a market cap of $99.00 million, a price-to-earnings ratio of -3.32 and a beta of 0.55. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in COYA. JPMorgan Chase & Co. bought a new position in Coya Therapeutics during the third quarter valued at about $28,000. CIBC Private Wealth Group LLC bought a new position in Coya Therapeutics during the fourth quarter valued at about $47,000. Occudo Quantitative Strategies LP bought a new position in Coya Therapeutics during the fourth quarter valued at about $66,000. Northwestern Mutual Wealth Management Co. bought a new position in Coya Therapeutics during the second quarter valued at about $119,000. Finally, Millennium Management LLC bought a new position in Coya Therapeutics during the fourth quarter worth about $121,000. Institutional investors own 39.75% of the company’s stock.

Analysts Set New Price Targets

COYA has been the subject of several analyst reports. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research report on Friday, April 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Wall Street Zen raised shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.